IDT Biologika Acquires Gallant Custom Labs

IDT Biologika has acquired Gallant Custom Laboratories, based in Ontario, Canada. Gallant is authorized by the Canadian Food Inspection Agency (CFIA) to manufacture autogenous viral and bacterial vaccines.
 
“With its strong scientific focus, in-house research and development and production of autogenous vaccines for the Canadian market, Gallant is an outstanding match for the IDT Group,” said IDT Biologika CEO Dr. Ralf Pfirmann. “With this second acquisition in North America within just a few months, IDT Biologika is highlighting its expanding commitment to meeting the vaccine manufacturing needs in these key international markets.”
 
Gallant serves customers throughout Canada, particularly those who provide vaccines to the Canadian livestock and poultry industry. The company has in-house diagnostic laboratory facilities to identify viral and bacterial diseases in pigs, sheep, goats, cattle and poultry, and to subsequently manufacture and supply the appropriate autogenous vaccines corresponding to specific pathogens out of its Cambridge-based manufacturing facilities in Ontario. Gallant presently employs twelve people, and will continue to do business as “Gallant Customs Laboratories, an IDT Biologika company.”
 
Jackie Gallant, a microbiologist who founded the company 20 years ago, will retain her title as president of Gallant Customs Laboratories and serve as senior executive manager. She will  also sit on the IDT Scientific Advisory Board.
 
“As part of IDT, Gallant will now have opportunities to provide new technologies and services to the Canadian animal health market, said Ms. Gallant. “The current business will continue to thrive and grow with new investment from IDT. I see this as a perfect match of skills and expertise. Although IDT is much larger, it maintains a family-owned business philosophy that fits well into the existing culture at Gallant.”